Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the genotypic and phenotypic characteristics of a mono-rifampin-resistant (RIF(R)) Mycobacterium tuberculosis strain cluster (designated AU-RIF(R)) and the acquisition of additional drug resistance.
|
18498237 |
2008 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for Mycobacterium tuberculosis detection in clinical samples.
|
21849695 |
2011 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert MTB/RIF quantitation offers a new, standardized approach to measuring bacterial burden in the sputum of patients with tuberculosis.
|
21836139 |
2011 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
WHO recommends that Xpert MTB/RIF replaces smear microscopy for initial diagnosis of suspected HIV-associated tuberculosis or multidrug-resistant pulmonary tuberculosis, but no data exist for its use in children.
|
21764384 |
2011 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the usefulness of the Xpert® MTB/RIF assay in a country with an intermediate tuberculosis burden.
|
22981162 |
2012 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and rifampicin resistance.
|
23185139 |
2012 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF).
|
23209384 |
2012 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert® MTB/RIF in pleural fluid for the diagnosis of tuberculosis.
|
23827859 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that the Xpert assay should not be routinely used to detect M. tuberculosis in EBC, saliva, urine, or blood samples from HIV-negative patients suspected of having pulmonary tuberculosis.
|
24108610 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted an incremental cost-benefit analysis comparing the use of a single negative Xpert versus two negative sputum smears to release consecutive adult inpatients with presumed TB from respiratory isolation at an urban public hospital in the United States.
|
24278155 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among smear-positive TB samples (n = 17), all (100%) were detected by DTB and 94.1% and 93.3% by Xpert MTB/RIF and CTM-MTB, respectively.
|
23786563 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we position Xpert MTB/RIF in today's TB diagnostic landscape and describe its additional potential as an adjunct to surveillance and surveys, taking into account considerations of pricing and ethics.
|
23180585 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analysed the impact of the Xpert(®) MTB/RIF molecular test on health-care diagnostic delay among tuberculosis patients.
|
24670698 |
2014 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a prospective, cross-sectional study with 2-month follow-up comparing Xpert with standard strategies for evaluating outpatients for active pulmonary TB at the San Francisco Department of Public Health TB Clinic between May 2010 and June 2011.
|
24869625 |
2014 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tests are expensive, so current research evaluating the use of Xpert® MTB/RIF in TB programmes in high TB burden settings will help evaluate how this investment may help start treatment promptly and improve outcomes.
|
24448973 |
2014 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Xpert® MTB/RIF assay detects the presence of Mycobacterium tuberculosis and its resistance to rifampicin (RMP) directly in sputum samples.
|
25216843 |
2014 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Cepheid Xpert(®) MTB/RIF assay has been credited with revolutionizing laboratory testing to aid in the diagnosis of TB and rifampicin-resistant TB.
|
25373876 |
2015 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We screened 95 Mycobacterium tuberculosis clinical isolates including 20 rifampin resistant (RIF-R), 21 isoniazid resistant (INH-R) and 54 fully susceptible (S) isolates determined by proportion method of drug susceptibility testing.
|
25297024 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include GenoType MTBDRplus Version 2.0 (Hain Lifescience), Xpert® MTB/RIF (Cepheid) and Anyplex™ plus MTB/NTM/DR-TB Real-time detection (Seegene).
|
26553046 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid diagnostic systems, such as Xpert(®) MTB/RIF for tuberculosis (TB) diagnosis and drug susceptibility testing (DST), and programs that provide high-quality DOTS anti-tuberculosis treatment to patients in the unregulated private sector (public-private mix [PPM]), may help address these challenges, albeit at increased cost.
|
26260835 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence.
|
25609730 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To conduct a pragmatic evaluation of the Xpert(®) MTB/RIF assay in the diagnosis of tuberculosis (TB) among child contacts.
|
26260831 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the commercially available molecular diagnostic tests Xpert(®) MTB/RIF and GenoType(®) MTBDRplus both provided timely and accurate results compared to conventional phenotypic tests in detecting TB and rifampicin resistance.
|
25946358 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The four transport and storage supports showed a good sensitivity and specificity for the detection of resistance to RIF and INH in M. tuberculosis strains using the GenoType MTBDRplus.
|
26431352 |
2015 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The systematic use of Xpert will increase early TB case confirmation in children and represents a major advance but sensitivity of all tests remains unacceptably low.
|
25888462 |
2015 |